Boston Scientific appoints COO as Boston Scientific stock awaits results

Published on 10/19/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific names Joseph Fitzgerald COO effective January 1, 2027. Boston Scientific stock costs EUR 39.56 on October 19, 2026 before October 28 results.

Leadership transition and earnings date

Joseph Fitzgerald becomes chief operating officer on October 7, 2026, with three segments planned.
Second-quarter revenue reached USD 5.44 billion and net income was USD 907.0 million.
Boston Scientific stock trades at EUR 39.56 at 10:16 a.m. CEST at Lang & Schwarz on October 19, 2026.

Architektonisches 3D-Render eines geschwungenen Glas-Bürohochhauses mit Wasserspiegelanlage — Boston Properties US1011371077 präsentiert ein zeitgenössisches Architektur-Render eines Hochhauses mit urbanem Wasserspiegelplatz, Illustration mit AI erstellt.

Boston Scientific Corporation (ISIN US1011371077) was trading at EUR 39.56 at Lang & Schwarz on October 19, 2026 at 10:16 a.m. CEST. The company had appointed Joseph M. Fitzgerald as chief operating officer on October 7, effective January 1, 2027, according to Boston Scientific.

Leadership changes on January 1

Fitzgerald will oversee global operations, business units and regions. The company will also establish three reportable segments on January 1: Interventional Therapies, Rhythm Solutions and MedSurg, a structure that management said was designed to speed decisions and support investment allocation.

What does the new structure mean?

The reorganization gives investors a clear operating milestone ahead of the next results. Boston Scientific's second-quarter revenue was USD 5.44 billion, up 7.50 percent from the prior-year quarter, while net income attributable to common shareholders reached USD 907.0 million, according to the company's reported figures for the quarter ended June 30, 2026.

The operating margin was 22.00 percent in the second quarter. Operating cash flow was USD 1.47 billion for the same quarter, giving the planned structure a financial baseline rather than only a management narrative.

Three dated steps for Boston Scientific

On July 29, 2026, Boston Scientific reported second-quarter adjusted earnings per share of USD 0.86, above the USD 0.83 consensus estimate, while revenue reached USD 5.44 billion, according to MarketBeat. On September 9, 2026, manufacturing, order fulfillment and shipping operations had been restored after the cybersecurity disruption, as Yahoo Finance reported. On October 7, 2026, the COO appointment and three-segment structure became the latest corporate action.

When are the next milestones?

Boston Scientific is scheduled to report third-quarter 2026 results before the market opens on October 28, 2026, with an 8:00 a.m. ET conference call, according to MarketBeat. Fitzgerald's new role is scheduled to begin on January 1, 2027, alongside the operating reorganization.

Stock valuation and trading context

Boston Scientific's primary listing is on the New York Stock Exchange. The stock was last quoted there at USD 44.39 on October 16, 2026 at 4:00 p.m. ET, with a market capitalization of USD 64.3 billion and a 52-week range of USD 41.39 to USD 105.65. The euro quote places the immediate investor focus on the October 28 report and the company's response to the cybersecurity disruption and competitive pressure.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.